|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] MSL, Dupilumab
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
10.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Medical Representative
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
12.16 |
|
|
¸ÞµðÄ(ÁÖ) |
¸ÞµðÄ(ÁÖ) ÀÇ·á±â±â ¿¬±¸°³¹ß ´ã´çÀÚ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
»ó½Ãä¿ë |
05.11 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Quality Associate / fixed term until 202
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
03.03 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Quality Associate / fixed term until 202
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
3³â¡è |
ä¿ë½Ã |
02.25 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] MR For Rare Disease
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
12.06 |
|
|
(ÁÖ)À¯¿µÁ¦¾à |
[°æ·Â] PVÆÀ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
05.26 |
05.17 |
|
|
Pharmax Ogilvy Healthworld |
CRA ¸ðÁý(´ë¸®°úÀå±Þ)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.20 |
|
|
(ÁÖ)¼¿ïÁ¦¾à |
°³¹ßÇмú °æ·ÂÀÚ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
03.18 |
|
|
(ÁÖ)ºê·¹ÀÎÇãºê |
ÀÓ»ó½ÃÇè QA
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
03.15 |
|
|
(ÁÖ)Çѱ¹·Î½´ |
Onsite User Services Specialist
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇϹݱ⠻ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
07.09 |
|
|
(ÁÖ)ÇѸ²Å×Å©³î·ÎÁö |
ÀÇ·á¿ë ħ´ë ¿µ¾÷Á÷ ¸ðÁý(°æ·Â)
¼¿ï ¼Ãʱ¸ | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
12.08 |
|
|
(ÁÖ)ÀÌÁö¸ÞµðÄÄ |
(ÁÖ)ÀÌÁö¸ÞµðÄÄ ±¸¸Å/¹°·ù½Ã½ºÅÛ °³¹ßÀÚ °ø°³Ã¤¿ë
¼¿ï ¼Ãʱ¸ | Çз¹«°ü |
»ý»êÁö¿ø/¹°·ù/±¸¸Å |
2³â¡è |
ä¿ë½Ã |
10.13 |
|
|
ºê·¹ÀÎÇãºê |
¿Ü±¹°è ¼ö¼ú¿ë ÀÇ·á±â±â Product Manager
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
10.12 |
|
|
À§´Ï´õ½ºÄÁ¼³Æà |
¿Ü±¹°è»ç ¸¶ÄÉÆà 2³âÀÌ»ó
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
10.10 |
|